Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
NCT07231588

Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation

Led by University of Cincinnati · Updated on 2026-02-05

20

Participants Needed

1

Research Sites

47 weeks

Total Duration

On this page

Sponsors

U

University of Cincinnati

Lead Sponsor

P

Pendulum Therapeutics

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research is to determine if an oral probiotic, Pendulum Glucose Control (PGC), can be safely given to patients during pelvic radiation therapy (RT). The researchers will study if the probiotics lessen gastrointestinal toxicity during pelvic radiation.

CONDITIONS

Official Title

Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must have histologically confirmed malignancy requiring at least 30 Gy of pelvic radiation therapy to pelvic lymph nodes
  • Eligible cancers include lower GI cancers (anal, rectal), gynecologic cancers (cervical, vulvar, vaginal, endometrial), and prostate cancer with lymph node involvement
  • Age 18 years or older
  • ECOG performance status 2 or less (or Karnofsky score 60% or higher)
  • Ability to understand and willingness to sign informed consent
Not Eligible

You will not qualify if you...

  • Inflammatory bowel disease such as Crohn's or ulcerative colitis
  • Currently receiving other investigational agents (prior investigational agents may be allowed at PI discretion)
  • Uncontrolled illnesses or conditions that make participation unsafe
  • Prior or concurrent malignancies that may interfere with safety or efficacy assessment
  • Previous pelvic radiation therapy
  • Not recovered from gastrointestinal adverse events from prior cancer therapy
  • Presence of colostomy or ileostomy
  • Pregnancy (due to inability to receive radiotherapy)
  • Known intolerance or allergies to components of PGC probiotic or related antimicrobial therapies
  • Unable to swallow capsules
  • Absolute neutrophil count below 1500/uL

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Cincinnati Medical Center

Cincinnati, Ohio, United States, 45219

Actively Recruiting

Loading map...

Research Team

U

UCCC Clinical Trials Office

CONTACT

B

Bailey Nelson, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here